SI2370099T1 - Modificirani proteini RSV F in postopki njihove uporabe - Google Patents

Modificirani proteini RSV F in postopki njihove uporabe

Info

Publication number
SI2370099T1
SI2370099T1 SI200931470A SI200931470A SI2370099T1 SI 2370099 T1 SI2370099 T1 SI 2370099T1 SI 200931470 A SI200931470 A SI 200931470A SI 200931470 A SI200931470 A SI 200931470A SI 2370099 T1 SI2370099 T1 SI 2370099T1
Authority
SI
Slovenia
Prior art keywords
proteins
methods
modified rsv
rsv
modified
Prior art date
Application number
SI200931470A
Other languages
English (en)
Inventor
Peter Pushko
Yingyun Wu
Michael Massare
Ye Liu
Gale Smith
Bin Zhou
Original Assignee
Novavax, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42310119&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2370099(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novavax, Inc. filed Critical Novavax, Inc.
Publication of SI2370099T1 publication Critical patent/SI2370099T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18523—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18561—Methods of inactivation or attenuation
    • C12N2760/18562—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18571—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SI200931470A 2008-12-09 2009-12-09 Modificirani proteini RSV F in postopki njihove uporabe SI2370099T1 (sl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12112608P 2008-12-09 2008-12-09
US16907709P 2009-04-14 2009-04-14
US22478709P 2009-07-10 2009-07-10
EP09836751.9A EP2370099B1 (en) 2008-12-09 2009-12-09 Modified rsv f proteins and methods of their use
PCT/US2009/067269 WO2010077717A1 (en) 2008-12-09 2009-12-09 Modified rsv f proteins and methods of their use

Publications (1)

Publication Number Publication Date
SI2370099T1 true SI2370099T1 (sl) 2016-08-31

Family

ID=42310119

Family Applications (2)

Application Number Title Priority Date Filing Date
SI200931470A SI2370099T1 (sl) 2008-12-09 2009-12-09 Modificirani proteini RSV F in postopki njihove uporabe
SI200932062T SI3067064T1 (sl) 2008-12-09 2009-12-09 Modificirani RSV F proteini in postopki za njih uporabo

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI200932062T SI3067064T1 (sl) 2008-12-09 2009-12-09 Modificirani RSV F proteini in postopki za njih uporabo

Country Status (23)

Country Link
US (7) US8715692B2 (sl)
EP (3) EP3067064B1 (sl)
JP (4) JP5813513B2 (sl)
KR (2) KR101801213B1 (sl)
CN (2) CN102307591B (sl)
AU (1) AU2009333484B2 (sl)
BR (1) BRPI0922867B8 (sl)
CA (1) CA2746228C (sl)
CY (2) CY1117757T1 (sl)
DK (2) DK3067064T3 (sl)
ES (2) ES2796725T3 (sl)
HK (1) HK1161690A1 (sl)
HR (2) HRP20160859T1 (sl)
HU (2) HUE051666T2 (sl)
IL (2) IL213450B (sl)
LT (1) LT3067064T (sl)
MX (4) MX2011006205A (sl)
PL (2) PL2370099T3 (sl)
PT (2) PT2370099T (sl)
RU (1) RU2531510C2 (sl)
SG (2) SG10201500161XA (sl)
SI (2) SI2370099T1 (sl)
WO (1) WO2010077717A1 (sl)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160000902A1 (en) * 2003-07-11 2016-01-07 Novavax, Inc. Combination vaccine for respiratory syncytial virus and influenza
EP2367844A4 (en) * 2008-11-18 2012-08-01 Ligocyte Pharmaceuticals Inc RSV-F VLP AND MANUFACTURING METHOD AND METHOD OF USE THEREOF
US11446374B2 (en) 2008-12-09 2022-09-20 Novavax, Inc. Modified RSV F proteins and methods of their use
MX2011006205A (es) * 2008-12-09 2011-09-01 Novavax Inc Proteinas f del vrs modificadas y metodos de uso de las mismas.
HRP20220756T1 (hr) * 2009-07-15 2022-09-02 Glaxosmithkline Biologicals S.A. Proteinski pripravci rsv f i postupci za izradu istih
US20110097358A1 (en) * 2009-10-12 2011-04-28 Techno Vax, Inc. RESPIRATORY SYNCYTIAL VIRUS (RSV) VIRUS-LIKE PARTICLES (VLPs)
HUE034247T2 (en) * 2010-11-05 2018-02-28 Novavax Inc Rabies glycoprotein virus-like particles (VLP-K)
WO2012089231A1 (en) * 2010-12-30 2012-07-05 Okairòs Ag Paramyxovirus vaccines
TR201908715T4 (tr) 2011-01-26 2019-07-22 Glaxosmithkline Biologicals Sa Rsv immünizasyon rejimi.
EP2739307B1 (en) * 2011-08-01 2017-09-06 Emory University Vlps containing ligands and methods related thereto
JP6085886B2 (ja) 2011-08-29 2017-03-01 国立大学法人徳島大学 Ｒｓｖ粘膜ワクチン
SG10201602434UA (en) * 2011-09-30 2016-05-30 Novavax Inc Recombinant nanoparticle rsv f vaccine for respiratory syncytial virus
CN103239734B (zh) * 2012-02-10 2016-02-24 北京艾棣维欣生物技术有限公司 用于预防和/或治疗呼吸道合胞病毒感染的疫苗
JP6523955B2 (ja) 2012-08-01 2019-06-05 バヴァリアン・ノルディック・アクティーゼルスカブ 組換え改変ワクシニアウイルスアンカラ（ｍｖａ）ｒｓウイルス（ｒｓｖ）ワクチン
EP2922570A1 (en) 2012-11-20 2015-09-30 GlaxoSmithKline Biologicals SA Rsv f prefusion trimers
RU2015138530A (ru) * 2013-02-11 2017-03-20 Новавакс, Инк. Комбинированная вакцина против респираторно-синцитиального вируса и вируса гриппа
DE102013004595A1 (de) * 2013-03-15 2014-09-18 Emergent Product Development Germany Gmbh RSV-Impfstoffe
CN105555306B (zh) 2013-09-19 2019-12-03 诺瓦瓦克斯股份有限公司 免疫原性中东呼吸综合征冠状病毒(MERS-CoV)组合物和方法
EP2974739A1 (en) 2014-07-15 2016-01-20 Novartis AG RSVF trimerization domains
WO2015195961A1 (en) * 2014-06-18 2015-12-23 Georgia State University And Research Foundation, Inc. Recombinant rsv reporter virus
TWI720946B (zh) * 2014-08-08 2021-03-11 美商Ｖｌｐ醫療股份有限公司 包含改質套膜蛋白質ｅ３之類病毒粒子
US9630994B2 (en) 2014-11-03 2017-04-25 University Of Washington Polypeptides for use in self-assembling protein nanostructures
KR102638978B1 (ko) 2015-07-07 2024-02-22 얀센 백신스 앤드 프리벤션 비.브이. Rsv에 대한 백신
CN114796474A (zh) * 2015-09-03 2022-07-29 诺瓦瓦克斯股份有限公司 具有改进的稳定性和免疫原性的疫苗组合物
RU2723039C2 (ru) 2015-12-23 2020-06-08 Пфайзер Инк. Мутанты белка f rsv
CA3018139A1 (en) 2016-04-05 2017-10-12 Janssen Vaccines & Prevention B.V. Vaccine against rsv
KR102421049B1 (ko) 2016-05-30 2022-07-15 얀센 백신스 앤드 프리벤션 비.브이. 안정화된 융합-전 rsv f 단백질
CN106011086A (zh) * 2016-06-15 2016-10-12 湖北省农业科学院畜牧兽医研究所 表达信号肽替换的呼吸道合胞病毒f蛋白的重组新城疫耐热疫苗株及制备方法
MA47787A (fr) * 2017-03-15 2020-01-22 Modernatx Inc Vaccin contre le virus respiratoire syncytial
SG11201908280SA (en) 2017-03-30 2019-10-30 Univ Queensland "chimeric molecules and uses thereof"
RU2019130167A (ru) 2017-04-04 2021-05-05 Юниверсити Оф Вашингтон Самосборные белковые наноструктуры, экспонирующие f-белки парамиксовируса и/или пневмовируса, и их применение
KR20200018483A (ko) 2017-06-14 2020-02-19 비로메틱스 아게 호흡기 합포체 바이러스에 대한 방어를 위한 고리형 펩티드
CN111148509A (zh) 2017-07-24 2020-05-12 诺瓦瓦克斯股份有限公司 治疗呼吸系统疾病的方法和组合物
WO2019148101A1 (en) 2018-01-29 2019-08-01 Modernatx, Inc. Rsv rna vaccines
CN112088014A (zh) 2018-02-28 2020-12-15 华盛顿大学 自组装纳米结构疫苗
SG11202009206QA (en) 2018-03-19 2020-10-29 Novavax Inc Multivalent influenza nanoparticle vaccines
EP3775174A4 (en) * 2018-03-30 2022-07-06 Georgia State University Research Foundation, Inc. RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINES
EP3773704A1 (en) 2018-04-03 2021-02-17 Sanofi Antigenic respiratory syncytial virus polypeptides
KR20200050264A (ko) * 2018-11-01 2020-05-11 에스케이바이오사이언스(주) 재조합 호흡기 세포융합 바이러스 f 단백질 및 이를 포함하는 백신 조성물
WO2020127728A1 (en) 2018-12-20 2020-06-25 Virometix Ag Lipopeptide building blocks and synthetic virus-like particles
WO2020175660A1 (ja) 2019-02-28 2020-09-03 Ｋｍバイオロジクス株式会社 Ｒｓｖ ｆ／ｇキメラワクチン
BR112022014830A2 (pt) * 2020-01-27 2022-09-27 Novavax Inc Formulações de vacina para coronavírus
US10953089B1 (en) 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations
CA3174215A1 (en) 2020-04-22 2021-10-28 Ugur Sahin Coronavirus vaccine
CN113855796B (zh) * 2021-07-30 2024-01-26 河北医科大学 卡介苗作为呼吸道合胞病毒灭活疫苗佐剂的应用
WO2023062651A1 (en) * 2021-10-13 2023-04-20 Padmanabh Patil Harshad Virus-like particles for respiratory syncytial virus and method of preparation thereof
US11878055B1 (en) 2022-06-26 2024-01-23 BioNTech SE Coronavirus vaccine
CN115927751A (zh) * 2022-09-17 2023-04-07 宁夏大学 牛呼吸道合胞体病毒实时荧光定量pcr检测的引物探针组及检测方法
CN118078975A (zh) * 2023-03-17 2024-05-28 成都威斯克生物医药有限公司 抗呼吸道合胞病毒感染的疫苗
CN118146321B (zh) * 2024-03-27 2024-08-27 普大生物科技(泰州)有限公司 一种rsv重组蛋白疫苗及其制备方法
CN118480560A (zh) * 2024-07-09 2024-08-13 北京悦康科创医药科技股份有限公司 呼吸道合胞病毒mRNA疫苗及其制备方法和应用

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149650A (en) 1986-01-14 1992-09-22 University Of North Carolina At Chapel Hill Vaccines for human respiratory virus
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US4911928A (en) 1987-03-13 1990-03-27 Micro-Pak, Inc. Paucilamellar lipid vesicles
GB8914968D0 (en) * 1989-06-29 1989-08-23 Connaught Lab Production of virus and purification of viral envelope proteins for vaccine use
US6387373B1 (en) 1993-01-15 2002-05-14 Novavax, Inc. Vaccines containing paucilsmellar lipid vesicles as immunological adjuvants
ES2370937T3 (es) 1993-09-13 2011-12-23 Protein Sciences Corporation Un método para producir vacunas antigripales polivalentes a base de hemaglutinina.
US5629021A (en) 1995-01-31 1997-05-13 Novavax, Inc. Micellar nanoparticles
US6020182A (en) * 1996-07-12 2000-02-01 Connaught Laboratories Limited Subunit respiratory syncytial virus vaccine preparation
CA2399321C (en) 2000-03-07 2013-04-30 Robert K. Evans Adenovirus formulations
AR030829A1 (es) 2000-10-02 2003-09-03 Smithkline Beecham Biolog Una formulacion de vacuna, procedimiento para la produccion de la misma, uso de dicha preparacion y un estuche para su administracion via intranasal
US20040063188A1 (en) 2002-02-14 2004-04-01 Novavax, Inc. Kit for treating gastrointestinal tract
AU2004273776B2 (en) 2003-04-25 2010-07-08 Medimmune, Llc Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus
EP1668112A4 (en) * 2003-06-20 2009-04-29 Protein Sciences Corp SARS IMMUNOGENOUS EXPRESSING VECTORS, SUCH VECTORS OR EXPRESSION PRODUCTS COMPRISING THOSE COMPOSITIONS, PROCESSES AND TESTS FOR THE PREPARATION AND USE THEREOF
EP1713824A2 (en) 2003-12-10 2006-10-25 The Uab Research Foundation Recombinant viruses with heterologous envelope proteins
WO2006099360A2 (en) 2005-03-10 2006-09-21 Medimmune Vaccines, Inc. Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences and methods for propagating virus
US7951384B2 (en) * 2005-08-05 2011-05-31 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
WO2007149490A1 (en) 2006-06-19 2007-12-27 Progenics Pharmaceuticals, Inc. Processes for recovering stabilized formulations of trimers of retroviral envelope (env) proteins
US20080233150A1 (en) * 2006-11-16 2008-09-25 Gale Smith Respiratory syncytial virus-virus like particle (vlps)
US8772256B2 (en) * 2006-11-30 2014-07-08 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Codon modified immunogenic compositions and methods of use
EP1972348A1 (en) * 2007-03-14 2008-09-24 Pierre Fabre Medicament Novel vaccine composition for the treatment of respiratory infectious diseases
JP2010522540A (ja) * 2007-03-21 2010-07-08 アイディー バイオメディカル コーポレイション オブ ケベック キメラ抗原
JP2010533737A (ja) 2007-07-19 2010-10-28 ノババックス，インコーポレイテッド キメラ水痘帯状疱疹ウイルス−ウイルス様粒子
EP4206231A1 (en) 2007-12-24 2023-07-05 ID Biomedical Corporation of Quebec Recombinant rsv antigens
BRPI0908861A2 (pt) 2008-02-25 2018-02-06 Novavax Inc partículas semelhantes a vírus de açucar vitrificado (vlps)
MX2011006205A (es) 2008-12-09 2011-09-01 Novavax Inc Proteinas f del vrs modificadas y metodos de uso de las mismas.
US11446374B2 (en) 2008-12-09 2022-09-20 Novavax, Inc. Modified RSV F proteins and methods of their use
CN107252482A (zh) 2009-05-27 2017-10-17 西莱克塔生物科技公司 具有不同释放速率的纳米载体加工组分
WO2010149745A1 (en) * 2009-06-24 2010-12-29 Glaxosmithkline Biologicals S.A. Recombinant rsv antigens
HRP20220756T1 (hr) * 2009-07-15 2022-09-02 Glaxosmithkline Biologicals S.A. Proteinski pripravci rsv f i postupci za izradu istih
HUE034247T2 (en) 2010-11-05 2018-02-28 Novavax Inc Rabies glycoprotein virus-like particles (VLP-K)
EP2729168A2 (en) * 2011-07-06 2014-05-14 Novartis AG Immunogenic compositions and uses thereof
SG10201602434UA (en) 2011-09-30 2016-05-30 Novavax Inc Recombinant nanoparticle rsv f vaccine for respiratory syncytial virus
US20140037680A1 (en) 2012-08-06 2014-02-06 Glaxosmithkline Biologicals, S.A. Novel method
RU2015138530A (ru) 2013-02-11 2017-03-20 Новавакс, Инк. Комбинированная вакцина против респираторно-синцитиального вируса и вируса гриппа
PL2988780T3 (pl) 2013-04-25 2019-06-28 Janssen Vaccines & Prevention B.V. Stabilizowane rozpuszczalne prefuzyjne polipeptydy F RSV
AU2014100888A4 (en) 2014-08-07 2014-09-11 Novartis Ag Virus clearance and protein purification methods
WO2017000105A1 (zh) * 2015-06-29 2017-01-05 尚平 便携式加湿器
CN114796474A (zh) 2015-09-03 2022-07-29 诺瓦瓦克斯股份有限公司 具有改进的稳定性和免疫原性的疫苗组合物

Also Published As

Publication number Publication date
CN102307591A (zh) 2012-01-04
JP2012511579A (ja) 2012-05-24
US20190134187A1 (en) 2019-05-09
JP2018007655A (ja) 2018-01-18
PL3067064T3 (pl) 2020-11-02
DK2370099T3 (en) 2016-08-01
EP3718566A1 (en) 2020-10-07
DK3067064T3 (da) 2020-06-08
KR101691574B1 (ko) 2017-01-02
WO2010077717A1 (en) 2010-07-08
US9731000B2 (en) 2017-08-15
HK1161690A1 (zh) 2012-08-03
PT2370099T (pt) 2016-07-14
JP5813513B2 (ja) 2015-11-17
US20150359872A1 (en) 2015-12-17
US9675685B2 (en) 2017-06-13
CY1123152T1 (el) 2021-10-29
SG10201500161XA (en) 2015-03-30
US20140294879A1 (en) 2014-10-02
EP2370099B1 (en) 2016-04-20
PL2370099T3 (pl) 2016-10-31
BRPI0922867B8 (pt) 2021-05-25
HUE051666T2 (hu) 2021-03-29
US20100239617A1 (en) 2010-09-23
HUE029037T2 (en) 2017-01-30
EP3718566B1 (en) 2024-06-12
HRP20200871T1 (hr) 2020-10-30
EP3067064A1 (en) 2016-09-14
MX358836B (es) 2018-09-05
KR20160148720A (ko) 2016-12-26
AU2009333484B2 (en) 2014-12-11
BRPI0922867A2 (pt) 2016-09-27
US8715692B2 (en) 2014-05-06
SI3067064T1 (sl) 2020-09-30
US20150266930A1 (en) 2015-09-24
AU2009333484A1 (en) 2011-07-21
RU2531510C2 (ru) 2014-10-20
US20150265698A1 (en) 2015-09-24
IL213450A0 (en) 2011-07-31
ES2582005T3 (es) 2016-09-08
IL247341B (en) 2018-04-30
MX345700B (es) 2017-02-10
CN106146671A (zh) 2016-11-23
RU2011128371A (ru) 2013-01-20
KR101801213B1 (ko) 2017-11-24
PT3067064T (pt) 2020-06-16
EP3067064B1 (en) 2020-05-13
KR20110112328A (ko) 2011-10-12
JP6782289B2 (ja) 2020-11-11
CY1117757T1 (el) 2017-05-17
US11052146B2 (en) 2021-07-06
JP6162751B2 (ja) 2017-07-12
BRPI0922867B1 (pt) 2020-09-29
SG172022A1 (en) 2011-07-28
EP2370099A4 (en) 2013-05-29
CA2746228A1 (en) 2010-07-08
ES2796725T3 (es) 2020-11-30
US10022437B2 (en) 2018-07-17
CA2746228C (en) 2021-05-18
CN102307591B (zh) 2016-08-03
JP2019069982A (ja) 2019-05-09
JP2015171378A (ja) 2015-10-01
HRP20160859T1 (hr) 2016-09-23
IL213450B (en) 2018-02-28
MX2011006205A (es) 2011-09-01
LT3067064T (lt) 2020-09-10
MX337932B (es) 2016-03-28
JP6462048B2 (ja) 2019-01-30
EP2370099A1 (en) 2011-10-05
US9717786B2 (en) 2017-08-01
CN106146671B (zh) 2020-03-31
US20230293667A1 (en) 2023-09-21

Similar Documents

Publication Publication Date Title
HRP20160859T1 (hr) Modificirani proteini rsv f i postupci njihove upotrebe
IL248723A0 (en) Specific antibodies against the bcr complex and methods of using them
HUE042940T2 (hu) Anti-FXI antitestek és alkalmazási eljárások
EP2373679A4 (en) HEPPIDINE MINI PEPTIDES AND METHODS OF USE
HK1147254A1 (en) 5-anilinoimidazopyridines and methods of use 5-
IL211623A0 (en) Anti-notch2 antibodies and methods of use
HK1149933A1 (en) Diazacarbazoles and methods of use
EP2367844A4 (en) RSV-F VLP AND MANUFACTURING METHOD AND METHOD OF USE THEREOF
PT2185719E (pt) Anticorpos anti-rantes e processos para a sua utilização
IL209548A0 (en) Diazacarbazoles and methods of use
IL206125A0 (en) Azaindolizines and methods of use
EP2346521A4 (en) PEPTIDES AND METHODS OF USE
ZA201100019B (en) Variant hhip1 protein and methods and uses thereof
IL213749A0 (en) Dgati nucleic acids and proteins and methods of use thereof
ZA201007681B (en) Cd4-related polypeptides and methods of use
EP2265117A4 (en) INHIBITORS OF PROTEIN PHOSPHATASE-1 AND USES THEREOF